PDCD1 and osteosarcoma: Other trials examining nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) and pembrolizumab plus cyclophosphamide (Immune system suppressor) for osteosarcoma therapy are ongoing (7).